Bioventus BVS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 68.3%+0.6pp | 67.7%+3.7pp | 64.1%-0.6pp | 64.6%-5.6pp | |
| Operating margin | 9.5%— | —— | -16.2%+16.5pp | -32.7%— | |
| Net margin | 4%+10.3pp | -6.3%+24.2pp | -30.5%+0.5pp | -31%-34.0pp | |
| Returns | |||||
| Return on equity | 13.7%+36.2pp | -22.5%+40.2pp | -62.6%-22.2pp | -40.5%— | |
| Return on invested capital | 11.9%+18.2pp | -6.3%+6.6pp | -12.9%+9.9pp | -22.8%— | |
| Efficiency | |||||
| Asset turnover | 0.8×+0.1× | 0.7×+0.3× | 0.5×+0.1× | 0.4×-0.1× | |
| Liquidity | |||||
| Current ratio | 1.7×+0.4× | 1.3×-0.2× | 1.5×+0.6× | 0.9×-0.6× | |
| Leverage | |||||
| Debt-to-equity | 1.7×-0.7× | 2.4×0.0× | 2.4×+1.1× | 1.3×+0.5× | |
| Net debt / EBITDA | 2.6×-15.3× | 17.9×— | —— | —— | |
| Per Share | |||||
| Book value per share | $2.67+16.6% | $2.29-17.3% | $2.77-47.7% | $5.30-47.5% | |
| Valuation | |||||
| Market capitalization | $659.19M+51.7% | $686.36M+106% | $332.54M+106% | $161.64M-81.6% | |
| Price / earnings | 23.1×— | —— | —— | —— | |
| Price / sales | 1.1×+0.4× | 1.2×+0.5× | 0.6×+0.3× | 0.3×-1.7× | |
| Price / book | 3.5×+0.6× | 4.6×+2.7× | 1.9×+1.4× | 0.5×-1.4× | |
| EV / EBITDA | 8.8×-35.4× | 56.8×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bioventus's profit margins?
- Bioventus (BVS) runs a 68.7% gross margin and a 10.0% operating margin, with a 4.9% net margin.
- Where do Bioventus's ratios come from?
- Every ratio is computed from Bioventus's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
